Theravance Biopharma, Inc. (NasdaqGM: TBPH)
Health Care · Pharmaceuticals · US
$17.03
+0.12% today · +23.3% 1Y
Theravance Biopharma, Inc. (NasdaqGM: TBPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $883.14M and employs 90 people.
Over the last twelve months the share price has gained 23.3%, trading between 13.08 and 21.03.
Tweenvest scores Theravance Biopharma, Inc. across four factors: quality 57/100, value 37/100, growth 67/100. Its strongest factor is growth.
TBPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $883.14M
- Revenue (TTM)
- $104.31M
- P/E
- 16.28
- EPS
- 1.05
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- $21.03
- 52-week low
- $13.08
- Avg volume (3M)
- —
- Shares outstanding
- 51.92M
- Employees
- 90
- Next earnings
- —
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
- ISIN
- KYG8807B1068
- Founded
- 2013
- Listed since
- May 16, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.